Evidence Level
Akkermansia muciniphila is a probiotic strain linked to metabolic health benefits. A 2019 randomized controlled trial by Depommier et al. demonstrated that pasteurized Akkermansia supplementation improved insulin sensitivity, reduced insulinemia by 28%, and decreased total cholesterol in overweight/obese volunteers over 3 months. Pasteurization enhances the bioavailability of Amuc_1100, a heat-stable protein associated with metabolic benefits (Depommier et al., 2019).
Recent studies further validate Akkermansia's efficacy. Zhang et al. (2025) conducted a 12-week RCT involving 58 overweight/obese individuals with type 2 diabetes and found that supplementation improved metabolic outcomes, particularly in those with low baseline levels of the bacterium. Additionally, Kang et al. (2024) reported that pasteurized Akkermansia HB05P enhanced muscle strength and function in a 12-week RCT.
As of 2025, Akkermansia has received Novel Food approval from the European Food Safety Authority (EFSA), confirming its safety profile for human consumption. These findings highlight Akkermansia's potential as a therapeutic intervention for metabolic disorders; however, further research is needed to fully elucidate its mechanisms and optimize its application.